A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer

被引:16
|
作者
Yamamoto, Noboru [1 ]
Tamura, Tomohide [1 ]
Kurata, Takayasu [2 ]
Yamamoto, Nobuyuki [3 ]
Sekine, Ikuo [1 ]
Kunitoh, Hideo [1 ]
Ohe, Yuichiro [1 ]
Saijo, Nagahiro [4 ]
机构
[1] Natl Canc Ctr, Div Internal Med, Chuo Ku, Tokyo 1040045, Japan
[2] Osaka Med Coll, Ctr Canc Chemotherapy, Osaka, Japan
[3] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[4] Natl Canc Ctr Hosp E, Kashiwa, Chiba, Japan
关键词
Nedaplatin; Dose-finding study; Pharmacokinetics; NSCLC; Elderly patient; III RANDOMIZED-TRIAL; PHASE-III; ANTITUMOR-ACTIVITY; CISPLATIN; CHEMOTHERAPY; PLATINUM; CARBOPLATIN; VINORELBINE; JAPAN;
D O I
10.1007/s00280-009-1006-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nedaplatin is a second-generation platinum showing favorable activity against non-small cell lung cancer (NSCLC). Dose-limiting toxicity (DLT) is thrombocytopenia, predicted by creatinine clearance (Ccr). This study was conducted to determine the recommended dose, and evaluate the toxicities, pharmacokinetics and efficacy for elderly NSCLC patients. Patients a parts per thousand yen70 years were stratified into two groups based on renal functions: Group A, Ccr a parts per thousand yen 60 and Group B, 40 a parts per thousand currency sign Ccr < 60. The initial doses were 80 and 60 mg/m(2) in Groups A and B, respectively. The doses were escalated in 20-mg/m(2) increments to 100 mg/m(2) until DLT. Chemotherapy-na < ve 39 elderly patients (Group A/Group B: 22/17) received a total of 83 cycles. Major toxicities were hematological. In Group A, one of the 15 patients at 100 mg/m(2) experienced DLT (neutropenia) and the recommended dose was determined at 100 mg/m(2). In Group B, three of the five patients had DLTs (leukopenia, neutropenia, thrombocytopenia and febrile neutropenia) at 100 mg/m(2), and the recommended dose was determined at 80 mg/m(2). The percentage decreases of neutrophil were well correlated with total and free-Pt AUCs. Partial responses were observed in 13 (33%) of the 39 patients, and 12 of the 13 patients who responded had a squamous cell carcinoma. Nedaplatin was administered simply and feasibly by stratifying renal function and exerted favorable antitumor activity for elderly patients with NSCLC, especially on squamous cell carcinoma.
引用
收藏
页码:79 / 88
页数:10
相关论文
共 50 条
  • [31] Weekly paclitaxel in elderly patients with advanced breast cancer: A dose-finding study
    Repetto L.
    Comandini D.
    Mammoliti S.
    Pietropaolo M.
    del Mastro L.
    Drugs in R & D, 2004, 5 (1) : 11 - 15
  • [32] Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer
    Oshita, Fumihiro
    Yamada, Kouzo
    Saito, Haruhiro
    Noda, Kazumasa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) : 465 - 470
  • [33] Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer
    Fumihiro Oshita
    Kouzo Yamada
    Haruhiro Saito
    Kazumasa Noda
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 465 - 470
  • [34] Importance of dose intensity in treatment of advanced non-small cell lung cancer in the elderly
    Prasad, Narayanan
    Bakshi, Ashish
    Deshmukh, Chetan
    Hingmire, Sachin
    Ranade, A. A.
    Parikh, Purvish
    SOUTH ASIAN JOURNAL OF CANCER, 2012, 1 (01) : 9 - 15
  • [35] Phase I/II study of amrubicin and nedaplatin in patients with untreated, advanced non-small cell lung cancer.
    Senju, Hiroaki
    Ogawara, Daiki
    Nakamura, Yoichi
    Fukuda, Minoru
    Nakatomi, Katsumi
    Gyotoku, Hiroshi
    Nakano, Hirofumi
    Yamaguchi, Hiroyuki
    Tomonaga, Nanae
    Ikeda, Takaya
    Mizoguchi, Kosuke
    Motoshima, Kohei
    Doi, Seiji
    Tsukamoto, Kazuhiro
    Kohno, Shigeru
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction
    Motonaga, Masanori
    Yamamoto, Noboru
    Makino, Yoshinori
    Ando-Makihara, Reiko
    Ohe, Yuichiro
    Takano, Mikihisa
    Hayashi, Yoshikazu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 713 - 721
  • [37] A phase II study of nedaplatin (CDGP) and docetaxel (TXT) in patients with advanced non-small cell lung cancer (NSCLC)
    Fujino, S.
    Asada, Y.
    Nakano, Y.
    Suzumura, Y.
    Inoue, S.
    Nagao, T.
    Hajiro, T.
    Tezuka, N.
    Sawai, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer
    Shepherd, FA
    Abratt, RP
    Anderson, H
    Gatzemeier, U
    Anglin, G
    Iglesias, J
    SEMINARS IN ONCOLOGY, 1997, 24 (02) : S50 - S55
  • [39] Oral vinorelbine in elderly patients with advanced non-small cell lung cancer
    Spasova, I.
    Davidova, R.
    Csemyova, S.
    Musil, J.
    LUNG CANCER, 2006, 52 : S41 - S42
  • [40] Outcome of elderly patients with advanced non-small cell lung cancer.
    Gumus, M
    Palak, B
    Iyikesici, S
    Yumuk, PF
    Seker, M
    Topal, A
    Dane, F
    Salepci, T
    Yayla, A
    Turhal, NS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 706S - 706S